PMID- 15866698
OWN - NLM
STAT- MEDLINE
DCOM- 20060615
LR  - 20050503
IS  - 0198-8859 (Print)
IS  - 0198-8859 (Linking)
VI  - 66
IP  - 4
DP  - 2005 Apr
TI  - Intravenous immunoglobulin induction treatment in flow cytometry 
      cross-match-positive kidney transplant recipients.
PG  - 359-63
AB  - Many recent studies have demonstrated increased acute humoral, cellular, 
      subclinical, or chronic rejection, and decreased allograft survival in flow 
      cytometry cross-match-positive kidney transplant recipients. The use of newer 
      techniques and more sensitive of enzyme-linked immunosorbent assay (ELISA) or 
      Flow Beads (microparticle based methods), donor-specific anti-human leukocyte 
      antigen (HLA) antibodies have been detected in these immunologically high-risk 
      patients. Intravenous immunoglobulin (IVIG) has immunomodulatory effects and has 
      been demonstrated to downregulate anti-HLA antibodies in highly sensitized 
      dialysis patients awaiting transplantation. Our initial studies demonstrate that 
      IVIG induction treatment is promising in flow cytometry cross-match-positive 
      kidney transplant recipients, and thus, those patients should not be excluded 
      from receiving transplantation despite a positive flow cytometry cross match. 
      Further studies with long-term follow-up are required to determine the effective 
      dose and duration of IVIG treatment, and additional studies are needed to 
      determine the most accurate tests for risk stratification.
FAU - Akalin, Enver
AU  - Akalin E
AD  - Nephrology, Mount Sinai School of Medicine, New York, NY, USA.; Recanati/Miller 
      Transplantation Institute, Mount Sinai School of Medicine, New York, NY 
      10029-6574, USA. enver.akalin@msnyuhealth.org
FAU - Bromberg, Jonathan S
AU  - Bromberg JS
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (HLA Antigens)
RN  - 0 (Isoantibodies)
SB  - IM
MH  - *Flow Cytometry
MH  - Graft Rejection/immunology/*prevention & control
MH  - HLA Antigens/*immunology
MH  - *Histocompatibility Testing
MH  - Humans
MH  - Isoantibodies/adverse effects/*biosynthesis
MH  - Kidney Failure, Chronic/immunology/therapy
MH  - Kidney Transplantation/*immunology
RF  - 29
EDAT- 2005/05/04 09:00
MHDA- 2006/06/16 09:00
CRDT- 2005/05/04 09:00
PHST- 2004/12/15 00:00 [received]
PHST- 2005/01/19 00:00 [accepted]
PHST- 2005/05/04 09:00 [pubmed]
PHST- 2006/06/16 09:00 [medline]
PHST- 2005/05/04 09:00 [entrez]
AID - S0198-8859(05)00040-6 [pii]
AID - 10.1016/j.humimm.2005.01.027 [doi]
PST - ppublish
SO  - Hum Immunol. 2005 Apr;66(4):359-63. doi: 10.1016/j.humimm.2005.01.027.